{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/5fdc9eeac905802f836875d2?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Venetoclax combinations in mutant AML subtypes podcast: FLT3","description":"<p>During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about&nbsp;venetoclax combinations in patients with <em>FLT3</em>-mutated AML.</p><p><br></p><p>Emerging data on venetoclax combinations in patients with <em>FLT3</em>-mutated AML have been presented at ASH 2020. <em>FLT3</em> mutations are the most common mutations in patients with AML. </p><p><br></p><p>In this podcast, Daver discusses the results of a study comparing the combination of azacitidine plus venetoclax <em>versus</em> azacitidine plus placebo in patients with <em>FLT3</em>-mutated AML. He also talks about a study evaluating the combination of gilteritinib with venetoclax in patients with relapsed/refractory <em>FLT3</em>-mutated<em>&nbsp;</em>AML and reports the results of the first combination of decitabine + venetoclax + FLT3 inhibitor of clinician’s choice in patients with <em>FLT3</em>-mutated<em>&nbsp;</em>AML.</p>","author_name":"Scientific Education Support"}